293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin

Background

Cervical cancer is a global public health issue. Cisplatin-based chemoradiation is the standard treatment for locally advanced scenarios. However, the toxicity and prolonged infusion time associated with cisplatin necessitate the search for options that yield similar outcomes. The objective of this study will be to compare the effectiveness of carboplatin versus cisplatin in patients with locally advanced cervical cancer undergoing chemoradiation.

Methods

The current study is an observational, retrospective, longitudinal, and descriptive type of research. The sample consisted of 183 patients with locally advanced cervical cancer who underwent chemoradiation treatment at the National Institute of Neoplastic Diseases, Lima, Peru, in the years 2014-201.

Results

Ninety-five patients aged equal to or less than 50 years and 88 patients aged over 50 years were analyzed, corresponding to 52% and 48% of the sample, respectively. The squamous cell carcinoma subtype represented 90% of the sample (164 cases), and the most frequent stages were IIB and IIIC, at 64% and 27% respectively. The trend for complete responses was higher for cisplatin, 82% vs. 77% for carboplatin. Patients who received cisplatin experienced more adverse effects than those who received carboplatin; neutropenia, diarrhea, and vomiting were the most reported events. At a 5-year follow-up, there was a 41% reduction in the risk of recurrence for cisplatin treatment (p 0.055), with a hazard ratio for overall survival of 0.72. It was observed that those who achieved a complete response had better survival.

Conclusions

In summary, while cisplatin demonstrated greater efficacy in terms of overall survival, carboplatin stood out for its more favorable tolerance profile. This suggests that carboplatin could be a valid alternative for patients with a more delicate clinical condition who might face challenges with cisplatin-associated toxicity. These findings underscore the importance of considering both efficacy and tolerability when choosing the appropriate therapy for patients with locally advanced cervical cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

N. Valdiviezo.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.